Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzupacap sarotalocan versus sham in primary indeterminate lesions or small choroidal melanoma
NL-OMON59477Phase 3Active, not recruiting
- Sponsor
- Aura Biosciences, Inc.
- Start
- Dec 2024
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of belzupacap sarotalocan in choroidal melanoma and choroidal melanocytic lesion (CML) (2 arms), sponsored by Aura Biosciences, Inc. Primary endpoint: Time to reach tumor progression. Started Dec 2024; status: active, not recruiting.
02
Drugs
belzupacap sarotalocan
03
Conditions
choroidal melanomachoroidal melanocytic lesion (CML)
Beyond the preview
Go deeper on NL-OMON59477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59477.